A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: Impact of pirfenidone

Muscle and Nerve

Volumn 35, Issue 2, 2007, Pages 208-216

  Gosselin, Luc E ^a   Williams, Jacqueline E ^a   Personius, Kirkwood ^a   Farkas, Gaspar A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Connective tissue; Diaphragm; Drug therapy; Inflammation; Muscular dystrophy

Indexed keywords

COLLAGEN TYPE 1; GELATINASE A; GELATINASE B; HYDROXYPROLINE; MESSENGER RNA; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; COMPARATIVE STUDY; CONTROLLED STUDY; DIAPHRAGM MUSCLE; GASTROCNEMIUS MUSCLE; GENIOGLOSSUS MUSCLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; MUSCULAR DYSTROPHY; MYOFIBROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROSIS; ISOMETRIC CONTRACTION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PYRIDONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33846983921     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20681     Document Type: Article

References (35)

1. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995;96:1137-1144.
2. Bienkowski RS, Baum BJ, Crystal RG. Fibroblasts degrade newly synthesized collagen within the cell before secretion. Nature 1978;276:413-416.
3. Carpenter S, Karpati G. Duchenne muscular dystrophy: plasma membrane loss initiates muscle cell necrosis unless it is repaired. Brain 1979;102:147-161.
4. Cullen MJ, Jaros E. Ultrastructure of the skeletal muscle in the X chromosome-linked dystrophic (mdx) mouse. Comparison with Duchenne muscular dystrophy. Acta Neuropathol 1988;77:69-81.
5. Giannelli G, De Marzo A, Marinosci F, Antonaci S. Matrix metalloproteinase imbalance in muscle disuse atrophy. Histol Histopathol 2005;20:99-106.
6. Goldspink DF. Age-related changes of RNA and DNA in muscles of normal and dystrophic hamsters. Life Sci 1977;20:57-64.
7. Goldspink DF, Goldspink G. Age-related changes in protein turnover and ribonucleic acid of the diaphragm muscle of normal and dystrophic hamsters. Biochem J 1977;162:191-194.
8. Gosselin LE, Barkley JE, Spencer MJ, McCormick KM, Farkas GA. Ventilatory dysfunction in mdx mice: impact of tumor necrosis factor-alpha deletion. Muscle Nerve 2003;28:336-343.
9. Gosselin LE, Martinez DA. Impact of TNF-alpha blockade on TGF-beta1 and type I collagen mRNA expression in dystrophic muscle. Muscle Nerve 2004;30:244-246.
10. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, Martinez DA. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 2004;30:645-653.
11. Hartel JV, Granchelli JA, Hudecki MS, Pollina CM, Gosselin LE. Impact of prednisone on TGF-beta1 and collagen in diaphragm muscle from mdx mice. Muscle Nerve 2001;24:428-432.
12. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
13. Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loike JD, et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 1988;318:1363-1368.
14. Iannaccone S, Quattrini A, Smirne S, Sessa M, de Rino F, Ferini-Strambi L, et al. Connective tissue proliferation and growth factors in animal models of Duchenne muscular dystrophy. J Neurol Sci 1995;128:36-44.
15. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of Pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995;125:779-785.
16. Iyer SN, Margolin SB, Hyde DM, Giri SN. Lung fibrosis is ameliorated by Pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res 1998;24:119-132.
17. Kherif S, Lafuma C, Dehaupas M, Lachkar S, Fournier JG, Verdiere-Sahuque M, et al. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev Biol 1999;205:158-170.
18. Kovanen V, Suominen H, Heikkinen E. Connective tissue of "fast" and "slow" skeletal muscle in rats - effects of endurance training. Acta Physiol Scand 1980;108:173-180.
19. Kovanen V, Suominen H, Heikkinen E. Collagen of slow twitch and fast twitch muscle fibres in different types of rat skeletal muscle. Eur J Appl Physiol Occup Physiol 1984;52:235-242.
20. Laurent G. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol (Cell Physiol) 1987;252:C1-C9.
21. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. A novel anti-fibrotic agent Pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 2002;446:177-185.
22. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002;446:167-176.
23. Passerini L, Bernasconi P, Baggi F, Confalonieri P, Cozzi F, Cornelio F, et al. Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. Neuromuscul Disord 2002;12:828-835.
24. Pastoret C, Sebille A. Further aspects of muscular dystrophy in mdx mice. Neuromuscul Disord 1993;3:471-475.
25. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993;90:3710-3714.
26. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 2002;11:263-272.
27. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, Pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999;159:1061-1069.
28. Robertson TA, Maley MA, Grounds MD, Papadimitriou JM. The role of macrophages in skeletal muscle regeneration with particular reference to chemotaxis. Exp Cell Res 1993;207:321-331.
29. Shihab FS, Bennett WM, Yi H, Andoh TF. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002;2:111-119.
30. Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int 1997;63 (suppl):S239-243.
31. Spencer MJ, Tidball JG. Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul Disord 2001;11:556-564.
32. Spond J, Case N, Chapman RW, Crawley Y, Egan RW, Fine J, et al. Inhibition of experimental acute pulmonary inflammation by Pirfenidone. Pulm Pharmacol Ther 2003;16:207-214.
33. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991;352:536-539.
34. Turner PR, Fong PY, Denetclaw WF, Steinhardt RA. Increased calcium influx in dystrophic muscle. J Cell Biol 1991;115:1701-1712.
35. Zimmerman SD, McCormick RJ, Vadlamudi RK, Thomas DP. Age and training alter collagen characteristics in fast- and slow-twitch rat limb muscle. J Appl Physiol 1993;75:1670-1674.